Cancers,
Journal Year:
2022,
Volume and Issue:
14(8), P. 2018 - 2018
Published: April 16, 2022
Hepatocellular
carcinoma
(HCC)
is
the
most
frequent
primary
liver
tumor.
As
a
result
of
advanced
disease
being
often
present
at
diagnosis,
only
small
percentage
patients
are
amenable
to
curative-intent
treatment
options
such
as
surgical
resection
and
transplantation.
Systemic
therapy
consisting
tyrosine
kinase
inhibitors
sorafenib
had
been
used
for
over
decade
with
limited
efficacy.
More
recently,
immune
checkpoint
has
revolutionized
landscape
various
malignant
tumors.
With
this
shifting
paradigm,
recent
data
have
demonstrated
encouraging
outcomes
among
HCC.
In
particular,
several
trials
investigated
safety
efficacy
(ICI)
either
monotherapy
or
in
form
combined
treatments.
We
sought
provide
an
overview
clinical
HCC
well
highlight
predictors
response
immune-related
adverse
events
review
evidence
on
perioperative
administration
ICI
resectable
Translational Lung Cancer Research,
Journal Year:
2024,
Volume and Issue:
13(4), P. 861 - 874
Published: April 1, 2024
Background:
The
administration
of
immune
checkpoint
inhibitors
(ICIs)
in
advanced
non-small
cell
lung
cancer
(NSCLC)
with
oncogenic
driver
alterations
other
than
epidermal
growth
factor
receptor
(EGFR)
aroused
a
heated
discussion.
We
thus
aimed
to
evaluate
ICI
treatment
these
patients
real-world
routine
clinical
practice.
Methods:
A
multicenter,
retrospective
study
was
conducted
for
NSCLC
at
least
one
gene
alteration
(KRAS,
HER2,
BRAF,
MET,
RET,
ALK,
ROS1)
receiving
monotherapy
or
combination
treatment.
data
regarding
clinicopathologic
characteristics,
efficacy,
and
safety
were
investigated.
Results:
total
216
included,
the
median
age
60
years,
72.7%
male,
46.8%
had
smoking
history.
molecular
involved
KRAS
(n=95),
HER2
(n=42),
BRAF
(n=22),
MET
(n=21),
RET
(n=14),
ALK
ROS1
(n=8);
56.5%
received
immunotherapy
first-line,
rest
43.5%
treated
as
second-line
above.
For
entire
cohort
who
immunotherapy-based
regimens
progression-free
survival
(PFS)
7.5
months
overall
(OS)
24.8
months.
above,
PFS
4.7
OS
17.1
mutated
first-line
setting
7.8
26.1
months,
respectively.
Moreover,
KRAS-mutant
that
progressed
after
chemotherapy
5.9
Programmed
death
ligand
1
(PD-L1)
expression
level
not
consistently
associated
response
across
different
subsets.
In
group,
PD-L1
positivity
[tumor
proportion
score
(TPS)
≥1%]
better
according
multivariate
Cox
analysis.
No
statistically
significant
association
found
status,
age,
gender
efficacy
any
group
analyses.
Conclusions:
could
obtain
benefits
from
ICIs
either
treatment-naive
those
have
experienced
progression
chemotherapy,
positive
(TPS
>1%)
may
be
potential
predictor.
rearrangement,
exon
14
skipping
mutation,
V600E
effectiveness
single
combined
therapy
remains
limited,
therefore,
targeted
therapies
should
considered
prior
regimens.
Future
studies
address
investigation
predictive
biomarkers
oncogene-driven
NSCLC.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 27, 2024
The
suppressive
tumour
microenvironment
significantly
hinders
the
efficacy
of
immunotherapy
in
treating
solid
tumors.
In
this
context,
stromal
cells,
such
as
tumour-associated
fibroblasts,
undergo
changes
that
include
an
increase
number
and
function
immunosuppressive
cells.
Adenosine,
a
factor
promotes
growth,
is
produced
from
ATP
breakdown
markedly
elevated
microenvironment.
It
acts
through
specific
binding
to
adenosine
receptors,
with
A2A
A2B
receptor
being
primary
drivers
immunosuppression.
This
paper
presents
roles
various
receptors
different
microenvironments.
review
focus
on
cells
non-cellular
components
Additionally,
we
summarize
discuss
recent
advances
potential
trends
using
antagonists
combined
immunotherapy.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(8), P. 2018 - 2018
Published: April 16, 2022
Hepatocellular
carcinoma
(HCC)
is
the
most
frequent
primary
liver
tumor.
As
a
result
of
advanced
disease
being
often
present
at
diagnosis,
only
small
percentage
patients
are
amenable
to
curative-intent
treatment
options
such
as
surgical
resection
and
transplantation.
Systemic
therapy
consisting
tyrosine
kinase
inhibitors
sorafenib
had
been
used
for
over
decade
with
limited
efficacy.
More
recently,
immune
checkpoint
has
revolutionized
landscape
various
malignant
tumors.
With
this
shifting
paradigm,
recent
data
have
demonstrated
encouraging
outcomes
among
HCC.
In
particular,
several
trials
investigated
safety
efficacy
(ICI)
either
monotherapy
or
in
form
combined
treatments.
We
sought
provide
an
overview
clinical
HCC
well
highlight
predictors
response
immune-related
adverse
events
review
evidence
on
perioperative
administration
ICI
resectable
